Format

Send to

Choose Destination
Cell Stem Cell. 2012 Mar 2;10(3):244-58. doi: 10.1016/j.stem.2012.02.005.

Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.

Author information

1
Jawaharlal Nehru Center for Advanced Scientific Research, Jakkur, Bangalore 560064, India.

Abstract

The broad repertoire of secreted trophic and immunomodulatory cytokines produced by mesenchymal stem cells (MSCs), generally referred to as the MSC secretome, has considerable potential for the treatment of cardiovascular disease. However, harnessing this MSC secretome for meaningful therapeutic outcomes is challenging due to the limited control of cytokine production following their transplantation. This review outlines the current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart disease. We discuss ongoing investigative directions aimed at improving cellular activity and characterizing the secretome and its regulation in greater detail. Finally, we provide insights on and perspectives for future development of the MSC secretome as a therapeutic tool.

PMID:
22385653
PMCID:
PMC3294273
DOI:
10.1016/j.stem.2012.02.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center